<DOC>
	<DOC>NCT02452801</DOC>
	<brief_summary>This study will evaluate the effect of various degrees of hepatic function on the pharmacokinetics and safety of ALKS 5461.</brief_summary>
	<brief_title>Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>For all subjects: Has a body mass index (BMI) of 18.035.0 kg/m2 and a total body weight &gt;50 kg Agrees to use an approved method of contraception for the duration of the study Additional criteria may apply For subjects with hepatic impairment: Has mild, moderate, or severe hepatic impairment Has hepatic dysfunction due to hepatocellular disease Additional criteria may apply For all subjects: Has any past history or current finding of a clinically significant observed abnormality, psychiatric or medical condition other than hepatic impairment Has a history of gastrointestinal surgery, excluding appendectomy or cholecystectomy Is pregnant, planning to become pregnant, or lactating Has a history of clinically significant allergy or a hypersensitivity to opioids Additional criteria may apply For subjects with hepatic impairment: Has evidence of hepatocellular carcinoma, acute liver disease, biliary obstruction, severe ascites, severe portal hypertension, surgical systemic shunts, or other clinically relevant liverrelated disorder or condition Has received a liver transplant Has had esophageal variceal bleeding in the past 2 months Additional criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>